419 related articles for article (PubMed ID: 16595643)
21. Drug resistant leprosy--a comparison between proven dapsone and proven thiambutosine resistance.
Waters MF; Pearson JM; Rees RJ
Int J Lepr Other Mycobact Dis; 1976; 44(1-2):152-3. PubMed ID: 776850
[No Abstract] [Full Text] [Related]
22. Activity of the combination of isoniazid, protionamide and dapsone against Mycobacterium leprae and some other mycobacteria.
Pattyn SR; Portaels F; Van Loo G; Van den Breen L
Arzneimittelforschung; 1981; 31(12):2155-7. PubMed ID: 7037011
[TBL] [Abstract][Full Text] [Related]
23. An experimental study of the antileprosy activity of a series of thioamides in the mouse.
Shepard CC; Jenner PJ; Ellard GA; Lancaster RD
Int J Lepr Other Mycobact Dis; 1985 Dec; 53(4):587-94. PubMed ID: 3910748
[TBL] [Abstract][Full Text] [Related]
24. Concepts behind the development of multiple drug therapy regimens in leprosy.
Waters MF
Lepr Rev; 1986 Dec; 57 Suppl 1():61-7. PubMed ID: 3295437
[No Abstract] [Full Text] [Related]
25. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
Dhople AM
Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
[TBL] [Abstract][Full Text] [Related]
26. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648.
Tomioka H; Saito H
Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):255-8. PubMed ID: 8371034
[TBL] [Abstract][Full Text] [Related]
27. Dapsone resistance in Mycobacterium leprae.
Gillis TP; Williams DL
Lepr Rev; 2000 Dec; 71 Suppl():S91-5. PubMed ID: 11201896
[TBL] [Abstract][Full Text] [Related]
28. Primary dapsone resistance in Cebu, The Philippines; cause for concern.
dela Cruz E; Cellona RV; Balagon MV; Villahermosa LG; Fajardo TT; Abalos RM; Tan EV; Walsh GP
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):253-6. PubMed ID: 8862258
[TBL] [Abstract][Full Text] [Related]
29. [Comparative characterization of the antigenic composition of M. leprae and M. lufu].
Salamatina OS; Diachina MN; Iushchenko AA; Chernousova LN; Kalinina ON; Parshin MP
Probl Tuberk; 2001; (8):49-51. PubMed ID: 11767394
[TBL] [Abstract][Full Text] [Related]
30. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
Pattyn SR; Hébrant F
Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
[TBL] [Abstract][Full Text] [Related]
31. Antimycobacterial activity of 2-acetylpyridine thiosemicarbazones in relation to their antileprosy activity.
Morrison NE; Collins FM
Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):180-6. PubMed ID: 7196888
[TBL] [Abstract][Full Text] [Related]
32. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
33. In vitro resistance test of human leprosy bacilli to anti-leprous drugs.
Ishihara S; Hagiwara S; Fujuda T
Microbios; 1977; 19(76):117-23. PubMed ID: 366337
[TBL] [Abstract][Full Text] [Related]
34. Screening of drugs for activity against Mycobacterium leprae.
Baohong J; Matsuo Y; Colston MJ
Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):836-42. PubMed ID: 3325576
[No Abstract] [Full Text] [Related]
35. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
[TBL] [Abstract][Full Text] [Related]
36. Concepts behind the development of multiple drug therapy regimens in leprosy.
Waters MF
Ethiop Med J; 1986 Dec; 24 Suppl 1():61-7. PubMed ID: 3301333
[No Abstract] [Full Text] [Related]
37. Primary dapsone-resistant leprosy in Cebu, Philippines.
Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC
Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607
[TBL] [Abstract][Full Text] [Related]
38. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
39. Primary dapsone resistant Mycobacterium leprae in a non endemic country.
Jamil A; Noor NM; Osman AS; Baseri MM; Muthupalaniappen L
Indian J Dermatol Venereol Leprol; 2013; 79(4):527-9. PubMed ID: 23760326
[No Abstract] [Full Text] [Related]
40. Inhibition of phenolic glycolipid-I synthesis in extracellular Mycobacterium leprae as an indicator of antimicrobial activity.
Harris EB; Franzblau SG; Hastings RC
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):588-91. PubMed ID: 3065422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
